Get the Stockscreener App
69.40
0.88%
0.5901
Tarsus Pharmaceuticals Inc stock is traded at $69.40, with a volume of 259.42K.
It is up +0.88% in the last 24 hours and up +6.51% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$68.81
Open:
$68.76
24h Volume:
259.42K
Relative Volume:
0.39
Market Cap:
$2.93B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-14.96
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+1.83%
1M Performance:
+6.51%
6M Performance:
+46.57%
1Y Performance:
+46.76%
1-Day Range:
$67.50
$70.16
1-Week Range:
$66.31
$70.84
52-Week Range:
$38.51
$76.81
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
69.33 | 2.90B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Top chart patterns to watch in Tarsus Pharmaceuticals Inc.2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
Does Tarsus Pharmaceuticals Inc. fit your quant trading modelQuarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Is Tarsus Pharmaceuticals Inc. stock a safe investment in uncertain marketsQuarterly Portfolio Report & Real-Time Volume Analysis - newser.com
What momentum indicators show for Tarsus Pharmaceuticals Inc. stockMarket Performance Summary & Consistent Growth Stock Picks - newser.com
Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance
What catalysts could drive Tarsus Pharmaceuticals Inc. stock higherWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
What's Next For Tarsus As Cash Reserves Fuel Pipeline And Global Reach? - RTTNews
Is Tarsus Pharmaceuticals Inc. stock cheap at current valuationWeekly Stock Analysis & Community Verified Trade Signals - newser.com
Is Tarsus Pharmaceuticals Inc. showing signs of accumulationTreasury Yields & Low Drawdown Trading Techniques - newser.com
How analysts rate Tarsus Pharmaceuticals Inc. stock todayEarnings Performance Report & Reliable Breakout Forecasts - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
Can Tarsus Pharmaceuticals Inc. stock sustain market leadershipMarket Growth Review & Growth-Oriented Investment Plans - newser.com
Can Tarsus Pharmaceuticals Inc. recover in the next quarterQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
Is Tarsus Pharmaceuticals Inc. stock poised for growth2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Forecasting Tarsus Pharmaceuticals Inc. price range with options dataEarnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
What’s the recovery path for long term holders of Tarsus Pharmaceuticals Inc.Market Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Tarsus Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Tarsus Pharmaceuticals (TARS) to Release Earnings on Tuesday - MarketBeat
What to expect from Tarsus Pharmaceuticals Inc. in the next 30 days2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Jennison Associates LLC Trims Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Applying sector rotation models to Tarsus Pharmaceuticals Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder value2025 Market Overview & Weekly High Return Opportunities - newser.com
Tarsus Pharmaceuticals Inc. stock trend outlook and recovery pathGold Moves & Risk Controlled Stock Alerts - newser.com
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):